RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2025 · 67 positions · Total reported value $8.12B · Top-10 concentration 63.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 67 equity positions with a combined reported value of $8.12B. The filing implies a focused portfolio: its ten largest positions account for 63.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were ASND ($2.04B), RYTM ($573.76M), PCVX ($431.01M). By sector, the heaviest allocations are Health Care 82.7%, Materials 0.1%. Versus the prior quarter, allocation shifted toward Other (+3.1pp) and away from Health Care (-2.9pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2025 were NUVL ($107.79M), BLTE ($64.75M), LBRX ($28.06M).

Of the 11 positions fully exited versus the prior quarter, the largest were DYN ($92.48M), RXST ($48.14M), TRML ($40.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • NUVL NUVALENT INC · $107.79M
  • BLTE BELITE BIO INC · $64.75M
  • LBRX LB PHARMACEUTICALS INC · $28.06M
  • ASMB ASSEMBLY BIOSCIENCES INC · $26.12M
  • CTNM CONTINEUM THERAPEUTICS INC · $24.93M
  • IVVD INVIVYD INC · $18.83M
  • PRME PRIME MEDICINE INC · $16.62M
  • QURE UNIQURE NV · $11.67M

Fully Exited (vs previous quarter)

  • DYN DYNE THERAPEUTICS INC · prev qtr: $92.48M
  • RXST RXSIGHT INC · prev qtr: $48.14M
  • TRML TOURMALINE BIO INC · prev qtr: $40.60M
  • ELVN ENLIVEN THERAPEUTICS INC · prev qtr: $17.03M
  • HNGE HINGE HEALTH INC · prev qtr: $15.53M
  • OMDA OMADA HEALTH INC · prev qtr: $7.32M
  • BBNX BETA BIONICS INC · prev qtr: $7.28M
  • TXG 10X GENOMICS INC · prev qtr: $5.50M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 82.7%
Materials 0.1%
Other 17.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.04B 25.19%
25.19%
Hold
2 5.68M $573.76M 7.07%
7.07%
Add
3 11.97M $431.01M 5.31%
5.31%
Hold
4 8.64M $376.49M 4.64%
4.64%
Add
5 3.37M $322.28M 3.97%
3.97%
Hold
6 10.45M $307.20M 3.79%
3.79%
Hold
7 19.89M $292.38M 3.60%
3.60%
Hold
8 10.14M $288.35M 3.55%
3.55%
Hold
9 7.32M $277.72M 3.42%
3.42%
Add
10 11.19M $273.48M 3.37%
3.37%
Hold
11 3.04M $249.30M 3.07%
3.07%
Hold
12 4.18M $194.65M 2.40%
Form 4 · 3 →
2.40%
Hold
13 12.20M $170.66M 2.10%
2.10%
Hold
14 10.43M $169.15M 2.08%
2.08%
Add
15 18.20M $133.24M 1.64%
Form 4 · 1 →
1.64%
Hold
16 7.00M $131.59M 1.62%
1.62%
Hold
17 2.87M $112.81M 1.39%
1.39%
Hold
18 6.96M $109.84M 1.35%
1.35%
Hold
19 7.68M $109.78M 1.35%
1.35%
Hold
20 10.86M $109.15M 1.34%
1.34%
Hold
21 1.25M $107.79M 1.33%
1.33%
New
22 1.58M $104.22M 1.28%
1.28%
Hold
23 1.98M $96.58M 1.19%
Form 4 · 1 →
1.19%
Reduce
24 10.23M $94.11M 1.16%
1.16%
Hold
25 20.06M $92.70M 1.14%
1.14%
Add
26 60.38M $82.72M 1.02%
1.02%
Hold
27 23.56M $77.03M 0.95%
0.95%
Hold
28 875.00K $64.75M 0.80%
0.80%
New
29 31.42M $63.15M 0.78%
Form 4 · 4 →
0.78%
Hold
30 1.17M $43.45M 0.54%
0.54%
Add
31 1.52M $42.49M 0.52%
0.52%
Hold
32 511.21K $41.75M 0.51%
0.51%
Hold
33 4.56M $39.65M 0.49%
0.49%
Hold
34 5.81M $35.86M 0.44%
0.44%
Hold
35 675.52K $35.35M 0.44%
0.44%
Hold
36 9.85M $28.28M 0.35%
0.35%
Hold
37 1.78M $28.06M 0.35%
0.35%
New
38 1.15M $27.48M 0.34%
0.34%
Hold
39 1.02M $26.12M 0.32%
0.32%
New
40 14.93M $25.53M 0.32%
0.32%
Hold
41 2.12M $24.93M 0.31%
0.31%
New
42 10.81M $22.37M 0.28%
0.28%
Hold
43 6.05M $19.53M 0.24%
0.24%
Hold
44 17.12M $18.83M 0.23%
0.23%
New
45 2.00M $16.80M 0.21%
0.21%
Hold
46 3.00M $16.62M 0.20%
0.20%
New
47 1.14M $15.45M 0.19%
0.19%
Hold
48 8.34M $15.10M 0.19%
0.19%
Hold
49 6.68M $13.16M 0.16%
0.16%
Hold
50 200.00K $11.67M 0.14%
0.14%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2025-Q3?

In its 2025-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 67 equity positions worth $8.12B in aggregate; its largest disclosed positions were ASND ($2.04B), RYTM ($573.76M), PCVX ($431.01M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $8.12B of long equity holdings across 67 positions as of 2025-Q3. Top-10 holdings account for 63.9% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →